NR-20324_结核分枝杆菌,菌株CDC1551,KnockoutGateway?克隆集,在大肠杆菌中重组,板8(克隆)
The Mycobacterium tuberculosis (M. tuberculosis), Knockout Gateway? clone set consists of 8 plates which contain 641 sequence validated knockout clones from M. tuberculosis, strain CDC1551. Each open reading frame was constructed with a hygromycin selectable gene replacement marker in vector pDEST-YUB, a Gateway? compatible adaptation of the cosmid cloning vector pYUB854 and cloned in Escherichia coli (E. coli) DH10B-T1 cells. The final construct also contains the β-lactamase gene to confer ampicillin resistance for plasmid selection in E. coli. The sequence was validated by full length sequencing of each clone with greater than 1X coverage and a mutation rate of less than 0.2%.
Information related to the use of Gateway? Clones can be obtained from Invitrogen?. A PCR product representing a functional hygromycin resistance cassette was assembled with chromosomal amplicons of approximately 600 base pairs of the regions flanking each gene targeted for replacement. The three fragments (left flank, hygromycin resistance gene, right flank) were amplified and cloned into pDONR? entry vectors (Invitrogen?). Recombination was facilitated through an attB substrate (attB-PCR product or a linearized attB expression clone) with an attP substrate (pDONR? vector) to create an attL-containing entry clone using the three-fragment MultiSite Gateway? Pro method. The hygromycin resistance cassette was sequence verified and experimentally verified through hygromycin resistance of DH10B-T1 E. coli cells. The final destination construct was confirmed by restriction digestion analysis. Please refer to the Invitrogen? Gateway? Technology Manual for additional Gateway? product details.
Plate orientation and viability were confirmed for NR-20324.
Each inoculated well of the 96-well plate contains approximately 60 ?L of E. coli culture (strain DH10B-T1) in Luria Bertani (LB) Broth containing 100 ?g/mL ampicillin supplemented with 15% glycerol.
Clone plates are replicated using a BioMek? FX robot. Production in the 96-well format has increased risk of cross-contamination between adjacent wells. Individual clones should be purified (e.g. single colony isolation and purification using good microbiological practices) and sequence-verified prior to use. BEI Resources only confirms the clone plate orientation and viability of randomly picked clones. BEI Resources does not confirm or validate individual clone identities provided by the contributor.
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立,旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中,可以监控科学界对这些材料的访问和使用,并确保试剂的质量控制。
除了为传染病界提供材料外,BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势,包括安全存储、社区访问和分发;同时保护存款人的知识产权。只要有需要,BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月, ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料,包括由其他政府支持的研究项目存放的材料,将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中,涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。